David Hallifax

David Hallifax

Auto-generated profile, based on publicly available information

David Hallifax

Pharmacy, University of Manchester, United Kingdom

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2013 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
PGPatricio Godoy
Patricio Godoy
NHNicola J. Hewitt
Nicola J. Hewitt
UAUte Albrecht
Ute Albrecht
MAMelvin E. Andersen
Melvin E. Andersen
NANariman Ansari
Nariman Ansari
Jan G HengstlerJan G Hengstler
Jan G Hengstler
This review encompasses the most important advances in liver functions and hepatotoxicity and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested, zonated lobules, the liver consists of approximately 80 % hepatocytes and 20 % non-parenchymal cells, the latter being involved in a secondary phase that may dramatically aggravate the initial damage. Hepatotoxicity, as well as hepatic metabolism, is controlled by a set of nuclear receptors (including PXR, CAR, HNF-4α, FXR, LXR, SHP, VDR and PPAR) and signaling pathways. When isolating liver cells, some pathways are activated, e.g., the RAS/MEK/ERK pathway, whereas others are silenced (e.g. HNF-4α), resulting in up- and downregulation of hundreds of genes. An understanding of these changes is crucial for a correct interpretation of in vitro data. The possibilities and limitations of the most useful liver in vitro systems are summarized, including three-dimensional culture techniques, co-cultures with non-parenchymal cells, hepatospheres, precision cut liver slices and the isolated perfused liver. Also discussed is how closely hepatoma, stem cell and iPS cell-derived hepatocyte-like-cells resemble real hepatocytes. Finally, a summary is given of the state of the art of liver in vitro and mathematical modeling systems that are currently used in the pharmaceutical industry with an emphasis on drug metabolism, prediction of clearance, drug interaction, transporter studies and hepatotoxicity. One key message is that despite our enthusiasm for in vitro systems, we must never lose sight of the in vivo situation. Although hepatocytes have been isolated for decades, the hunt for relevant alternative systems has only just begun.

1 January 2007 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
NHNicola J. Hewitt
Nicola J. Hewitt
MLMaría José Gómez Lechón
María José Gómez Lechón
JHJ. Brian Houston
J. Brian Houston
DHDavid Hallifax
David Hallifax
HBHayley S. Brown
Hayley S. Brown
Jan G HengstlerJan G Hengstler
Jan G Hengstler
This review brings you up-to-date with the hepatocyte research on: 1) in vitro–in vivo correlations of metabolism and clearance; 2) CYP enzyme induction, regulation, and cross-talk using human hepatocytes and hepatocyte-like cell lines; 3) the function and regulation of hepatic transporters and models used to elucidate their role in drug clearance; 4) mechanisms and examples of idiosyncratic and intrinsic hepatotoxicity; and 5) alternative cell systems to primary human hepatocytes. We also report pharmaceutical perspectives of these topics and compare methods and interpretations for the drug development process.

27 July 2010 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
DHDavid Hallifax
David Hallifax
JFJoanne A. Foster
Joanne A. Foster
JHJ. Brian Houston
J. Brian Houston

1 April 2006 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
DHDavid Hallifax
David Hallifax
JHJ. Brian Houston
J. Brian Houston

1 November 2017 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
FWFrancesca Leanne Wood
Francesca Leanne Wood
JHJames Brian Houston
James Brian Houston
DHDavid Hallifax
David Hallifax
Although prediction of clearance using hepatocytes and liver microsomes has long played a decisive role in drug discovery, it is widely acknowledged that reliably accurate prediction is not yet achievable despite the predominance of hepatically cleared drugs. Physiologically mechanistic methodology tends to underpredict clearance by several-fold and empirical correction of this bias is confounded by imprecision across drugs. Understanding of the causes of prediction uncertainty has been slow, possibly reflecting poor resolution of variables associated with donor source and experimental methods, particularly for the human situation. Hallifax et al. (Pharm. Res. 27: 2150-2161, 2010) reported that among published human hepatocyte predictions there was a tendency for underprediction to increase with increasing in vivo intrinsic clearance, suggesting an inherent limitation using this particular system. This implied an artefactual rate limitation in vitro, although preparative effects on cell stability and performance were not yet resolved from assay design limitations. Here, to resolve these issues further, we present an up-to-date and comprehensive examination of predictions from published rat as well as human studies (n= 128 and 101, hepatocytes and n= 71 and 83, microsomes, respectively) to assess system performance more independently. We report a clear trend of increasing underprediction with increasing in vivo intrinsic clearance which is similar both between species and between in vitro systems. Hence, prior concerns arising specifically from human in vitro systems may be unfounded and the focus of investigation in future should be to minimise the potential in vitro assay limitations common to whole cells and subcellular fractions.

1 July 2005 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
AGAleksandra Galetin
Aleksandra Galetin
KIKiyomi Ito
Kiyomi Ito
DHDavid Hallifax
David Hallifax
JHJ. Brian Houston
J. Brian Houston
The complexity of in vitro kinetic phenomena observed for CYP3A4 substrates (homo- or heterotropic cooperativity) confounds the prediction of drug-drug interactions, and an evaluation of alternative and/or pragmatic approaches and substrates is needed. The current study focused on the utility of the three most commonly used CYP3A4 in vitro probes for the prediction of 26 reported in vivo interactions with azole inhibitors (increase in area under the curve ranged from 1.2 to 24, 50% in the range of potent inhibition). In addition to midazolam, testosterone, and nifedipine, quinidine was explored as a more “pragmatic” substrate due to its kinetic properties and specificity toward CYP3A4 in comparison with CYP3A5. Ki estimates obtained in human liver microsomes under standardized in vitro conditions for each of the four probes were used to determine the validity of substrate substitution in CYP3A4 drug-drug interaction prediction. Detailed inhibitor-related (microsomal binding, depletion over incubation time) and substrate-related factors (cooperativity, contribution of other metabolic pathways, or renal excretion) were incorporated in the assessment of the interaction potential. All four CYP3A4 probes predicted 69 to 81% of the interactions with azoles within 2-fold of the mean in vivo value. Comparison of simple and multisite mechanistic models and interaction prediction accuracy for each of the in vitro probes indicated that midazolam and quinidine in vitro data provided the best assessment of a potential interaction, with the lowest bias and the highest precision of the prediction. Further investigations with a wider range of inhibitors are required to substantiate these findings.